Reviewing Bullfrog AI (NASDAQ:BFRG) and Cartesian Therapeutics (NASDAQ:RNAC)

Cartesian Therapeutics (NASDAQ:RNAC) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Cartesian Therapeutics and Bullfrog AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$26.00 million	20.17	-$219.71 million	N/A	N/A
Bullfrog AI	$65,000.00	330.95	-$5.36 million	($0.88)	-3.11

Bullfrog AI has lower revenue, but higher earnings than Cartesian Therapeutics.

Profitability

This table compares Cartesian Therapeutics and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-424.47%	N/A	-5.85%
Bullfrog AI	N/A	-130.80%	-117.12%

Volatility & Risk

Cartesian Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Cartesian Therapeutics and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	1	7	0	2.88
Bullfrog AI	0	0	0	0	N/A

Cartesian Therapeutics currently has a consensus price target of $43.00, indicating a potential upside of 75.37%. Given Cartesian Therapeutics’ higher possible upside, research analysts plainly believe Cartesian Therapeutics is more favorable than Bullfrog AI.

Institutional & Insider Ownership

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 61.1% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Bullfrog AI on 8 of the 11 factors compared between the two stocks.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.